QUESTRAN

Questran Adverse Events Reported to the FDA Over Time

How are Questran adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Questran, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Questran is flagged as the suspect drug causing the adverse event.

Most Common Questran Adverse Events Reported to the FDA

What are the most common Questran adverse events reported to the FDA?

Diarrhoea	37 (4.37%)
Dehydration	25 (2.96%)
Alanine Aminotransferase Increased	19 (2.25%)
Aspartate Aminotransferase Increase...	19 (2.25%)
Renal Failure Acute	17 (2.01%)
Nausea	14 (1.65%)
Dysgeusia	13 (1.54%)
Gamma-glutamyltransferase Increased	12 (1.42%)
Blood Alkaline Phosphatase Increase...	11 (1.3%)
Constipation	11 (1.3%)
Drug Ineffective	11 (1.3%)
	Show More
Myalgia	11 (1.3%)
Renal Failure	10 (1.18%)
Vomiting	10 (1.18%)
Abdominal Pain	9 (1.06%)
Blood Creatine Phosphokinase Increa...	8 (.95%)
Blood Lactate Dehydrogenase Increas...	8 (.95%)
Organising Pneumonia	8 (.95%)
Pruritus	8 (.95%)
Arthralgia	7 (.83%)
Cough	7 (.83%)
Eosinophilia	7 (.83%)
Hepatic Enzyme Increased	7 (.83%)
Medication Error	7 (.83%)
Muscle Spasms	7 (.83%)
Renal Tubular Disorder	7 (.83%)
Abdominal Distension	6 (.71%)
Anxiety	6 (.71%)
Asthenia	6 (.71%)
Blood Cholesterol Increased	6 (.71%)
Dyspepsia	6 (.71%)
Fatigue	6 (.71%)
Histiocytosis Haematophagic	6 (.71%)
Rash	6 (.71%)
Weight Decreased	6 (.71%)
White Blood Cell Count Decreased	6 (.71%)
Abdominal Pain Upper	5 (.59%)
Aortic Aneurysm	5 (.59%)
Blood Sodium Decreased	5 (.59%)
Bursitis	5 (.59%)
Electrolyte Imbalance	5 (.59%)
Fall	5 (.59%)
Headache	5 (.59%)
Hepatitis Cholestatic	5 (.59%)
Liver Disorder	5 (.59%)
Lymphadenopathy	5 (.59%)
Muscular Weakness	5 (.59%)
Neoplasm Malignant	5 (.59%)
Neutropenia	5 (.59%)
Overdose	5 (.59%)
Pulmonary Embolism	5 (.59%)
Sarcoidosis	5 (.59%)
Acidosis Hyperchloraemic	4 (.47%)
Blood Triglycerides Increased	4 (.47%)
Cardio-respiratory Arrest	4 (.47%)
Deep Vein Thrombosis	4 (.47%)
Dry Mouth	4 (.47%)
Flatulence	4 (.47%)
General Physical Health Deteriorati...	4 (.47%)
Platelet Count Decreased	4 (.47%)
Pyrexia	4 (.47%)
Rectal Haemorrhage	4 (.47%)
Stevens-johnson Syndrome	4 (.47%)
Abdominal Discomfort	3 (.35%)
Aphonia	3 (.35%)
Breast Mass	3 (.35%)
C-reactive Protein Increased	3 (.35%)
Chest Pain	3 (.35%)
Coagulopathy	3 (.35%)
Decreased Appetite	3 (.35%)
Drug Intolerance	3 (.35%)
Drug Rash With Eosinophilia And Sys...	3 (.35%)
Dry Throat	3 (.35%)
Gastroenteritis	3 (.35%)
Hallucination	3 (.35%)
Hallucination, Auditory	3 (.35%)
Hyperhidrosis	3 (.35%)
Hypomagnesaemia	3 (.35%)
Hyponatraemia	3 (.35%)
Incorrect Dose Administered	3 (.35%)
Infusion Related Reaction	3 (.35%)
Iron Deficiency	3 (.35%)
Leukoencephalopathy	3 (.35%)
Malaise	3 (.35%)
Muscle Atrophy	3 (.35%)
Rhabdomyolysis	3 (.35%)
Sepsis	3 (.35%)
Skin Disorder	3 (.35%)
Stomatitis	3 (.35%)
Throat Irritation	3 (.35%)
Tumour Marker Increased	3 (.35%)
Adverse Event	2 (.24%)
Anaemia Macrocytic	2 (.24%)
Ascites	2 (.24%)
Blepharitis	2 (.24%)
Blood Bilirubin Increased	2 (.24%)
Blood Calcium Decreased	2 (.24%)
Blood Immunoglobulin M Increased	2 (.24%)
Blood Potassium Decreased	2 (.24%)
Blood Potassium Increased	2 (.24%)
Brain Oedema	2 (.24%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Questran, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Questran is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Questran

What are the most common Questran adverse events reported to the FDA?

Hepatobiliary	61 (7.21%)
Gastrointestinal Signs	59 (6.97%)
Gastrointestinal Motility And Defec...	51 (6.03%)
Electrolyte And Fluid Balance Condi...	36 (4.26%)
Epidermal And Dermal Conditions	34 (4.02%)
Muscle	32 (3.78%)
Renal Disorders	30 (3.55%)
Enzyme	27 (3.19%)
Neurological	27 (3.19%)
Hepatic And Hepatobiliary	24 (2.84%)
Hematology Investigations	23 (2.72%)
	Show More
Medication Errors	23 (2.72%)
Therapeutic And Nontherapeutic Effe...	22 (2.6%)
Respiratory	16 (1.89%)
White Blood Cell	16 (1.89%)
Water, Electrolyte And Mineral	15 (1.77%)
Infections - Pathogen Unspecified	12 (1.42%)
Lipid Analyses	11 (1.3%)
Lower Respiratory Tract Disorders	11 (1.3%)
Joint	9 (1.06%)
Appetite And General Nutritional	8 (.95%)
Injuries	8 (.95%)
Oral Soft Tissue Conditions	8 (.95%)
Anxiety Disorders	7 (.83%)
Nephropathies	7 (.83%)
Physical Examination Topics	7 (.83%)
Acid-base	6 (.71%)
Disturbances In Thinking	6 (.71%)
Headaches	6 (.71%)
Hematopoietic Neoplasms	6 (.71%)
Product Quality Issues	6 (.71%)
Aneurysms And Artery Dissections	5 (.59%)
Cardiac Arrhythmias	5 (.59%)
Immune	5 (.59%)
Immunology And Allergy	5 (.59%)
Miscellaneous And Site Unspecified ...	5 (.59%)
Pulmonary Vascular	5 (.59%)
Spleen, Lymphatic And Reticulendoth...	5 (.59%)
Synovial And Bursal	5 (.59%)
Body Temperature Conditions	4 (.47%)
Bone, Calcium, Magnesium And Phosph...	4 (.47%)
Embolism And Thrombosis	4 (.47%)
Encephalopathies	4 (.47%)
Gallbladder	4 (.47%)
Gastrointestinal Hemorrhages	4 (.47%)
Musculoskeletal And Connective Tiss...	4 (.47%)
Ocular Infections, Irritations And ...	4 (.47%)
Plasma Cell Neoplasms	4 (.47%)
Protein And Chemistry Analyses	4 (.47%)
Salivary Gland Conditions	4 (.47%)
Skin Appendage Conditions	4 (.47%)
Sleep Disorders	4 (.47%)
Vision	4 (.47%)
Administration Site Reactions	3 (.35%)
Bacterial Infectious	3 (.35%)
Breast	3 (.35%)
Coagulopathies And Bleeding Diathes...	3 (.35%)
Dental And Gingival Conditions	3 (.35%)
Iron And Trace Metal Metabolism	3 (.35%)
Allergic Conditions	2 (.24%)
Anemias Nonhemolytic And Marrow Dep...	2 (.24%)
Benign Neoplasms Gastrointestinal	2 (.24%)
Bone And Joint Injuries	2 (.24%)
Breast Neoplasms Malignant And Unsp...	2 (.24%)
Bronchial Disorders	2 (.24%)
Central Nervous System Vascular	2 (.24%)
Connective Tissue Disorders	2 (.24%)
Coronary Artery	2 (.24%)
Cutaneous Neoplasms Benign	2 (.24%)
Decreased And Nonspecific Blood Pre...	2 (.24%)
Deliria	2 (.24%)
Endocrine Neoplasms Malignant And U...	2 (.24%)
Fatal Outcomes	2 (.24%)
Gastrointestinal Neoplasms Malignan...	2 (.24%)
Gastrointestinal Vascular Condition...	2 (.24%)
Hematological And Lymphoid Tissue T...	2 (.24%)
Increased Intracranial Pressure And...	2 (.24%)
Lifestyle Issues	2 (.24%)
Lymphomas	2 (.24%)
Neonatal And Perinatal Conditions	2 (.24%)
Ocular Structural Change, Deposit A...	2 (.24%)
Peritoneal And Retroperitoneal Cond...	2 (.24%)
Platelet	2 (.24%)
Renal And Urinary Tract Investigati...	2 (.24%)
Respiratory And Mediastinal Neoplas...	2 (.24%)
Toxicology And Therapeutic Drug Mon...	2 (.24%)
Vascular Inflammations	2 (.24%)
Vitamin Related	2 (.24%)
Anal And Rectal Conditions	1 (.12%)
Bladder And Bladder Neck Disorders	1 (.12%)
Cardiac And Vascular Investigations	1 (.12%)
Chemical Injury And Poisoning	1 (.12%)
Cranial Nerve Disorders	1 (.12%)
Endocrine Investigations	1 (.12%)
Exocrine Pancreas Conditions	1 (.12%)
Eye Therapeutic Procedures	1 (.12%)
Gastrointestinal Conditions	1 (.12%)
Gastrointestinal Stenosis And Obstr...	1 (.12%)
Immunodeficiency Syndromes	1 (.12%)
Menstrual Cycle And Uterine Bleedin...	1 (.12%)
Mesotheliomas	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Questran, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Questran is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.